Denali Therapeutics stock sits 28.07 percent above its 52-week low on October 16, 2026

Published on 10/17/2026 at 20:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are estimated for November 5, 2026. Denali Therapeutics stock closed at USD 17.61 on October 16, 2026, down 3.98 percent versus prior close.

Trading range and results date

Denali Therapeutics stock stood 28.07 percent above its 52-week low on October 16, 2026.
MarketBeat estimates the next report for November 5, 2026.
Denali Therapeutics stock closed at USD 17.61 on October 16, 2026, down 3.98 percent versus the prior close of USD 18.34.
Market capitalization was USD 2.8 billion and the P/E ratio was minus 6.20 on October 16, 2026.

DNLI, US24823R1059, Illustration mit AI erstellt.

Denali Therapeutics stock stood 28.07 percent above its 52-week low of USD 13.75 on October 16, 2026, while its latest Nasdaq closing price was USD 17.61. The next reporting date is estimated for November 5, 2026, after the market closes, according to MarketBeat. At the October 16, 2026 close, the stock was down 3.98 percent from USD 18.34.

Quarterly figures set the baseline

Denali's second-quarter 2026 revenue was USD 3.60 million, versus a USD 2.15 million consensus estimate. Its diluted loss was USD 0.68 per share, a USD 0.17 wider loss than the consensus estimate, according to MarketBeat. The figures cover the quarter ended June 30, 2026. Denali's investor-relations page describes the company as a biotechnology group developing medicines designed to cross the blood-brain barrier through its TransportVehicle platform.

Range and volume define the move

The 52-week range was USD 13.75 to USD 27.30 as of October 16, 2026. The closing price was 35.49 percent below the yearly high and 28.07 percent above the yearly low. Trading volume reached 2,304,258 shares, 47.76 percent above the average volume of 1,559,376 shares.

Valuation meets the next date

Denali's market capitalization was USD 2.8 billion on October 16, 2026, while its trailing P/E ratio was minus 6.20. The company pays no dividend according to the quoted market figures. MarketBeat estimates the third-quarter 2026 report for November 5, 2026, after the market closes, with a conference call scheduled for 4:00 p.m. ET.

Comparison with peers

DNLI: minus 3.98 percent, P/E minus 6.20, market capitalization USD 2.8 billion

Vera Therapeutics (Nasdaq, USD): minus 2.42 percent, P/E minus 4.76, market capitalization USD 2.0 billion

Alumis (Nasdaq, USD): minus 3.01 percent, P/E minus 1.61, market capitalization USD 792.1 million

Closing level sets the frame

Denali's October 16 close left the stock below its yearly high but above its yearly low, with volume exceeding its average. The November 5 reporting date gives investors the next fixed point for assessing revenue and losses.